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Stlmmary 
The synthesis of leukotrienes in human blood neutrophils chiefly relies on the activity of two 
enzymes,  phospholipase  A2 and 5-1ipoxygenase (5-I.O).  In turn, the activation  of the 5-LO 
requires the participation of a recently characterized membrane-bound protein, the 5-LO-activating 
protein (FLAP). In this study, we have investigated conditions under which FLAP expression 
in neutrophils may be modulated. Of several  cytokines tested, only granulocyte/macrophage colony- 
stimulating factor (GM-CSF) (and to a lesser extent tumor necrosis factor cx) significantly increased 
expression of FLAP. GM-CSF increased FLAP mRNA steady-state levels in a time- and dose- 
dependent manner. The stimulatory effect of GM-CSF on FLAP mRNA was inhibited by prior 
treatment of the cells with the transcription  inhibitor, actinomycin D, and pretreatment of the 
cells with the protein synthesis inhibitor, cycloheximide, failed to prevent the increase in FLAP 
mRNA induced by GM-CSF. The accumulation of newly synthesized FLAP, as determined by 
immunoprecipitation after incorporation of 3sS-labeled amino acids, was also increased after 
incubation of neutrophils with GM-CSF. In addition, the total level of FLAP protein was increased 
in GM-CSF-treated neutrophils, as determined by two-dimensional gel electrophoresis, followed 
by Western blot. GM-CSF did not alter the stability of the FLAP protein, indicating that the 
effect of GM-CSF on FLAP accumulation was the consequence of increased de novo synthesis 
as opposed to decreased degradation of FLAP. Finally, incubation of neutrophils with the synthetic 
glucocorticoid dexamethasone directly stimulated the upregulation of FLAP mRNA and protein, 
and enhanced the effect of GM-CSF. Taken together, these data demonstrate that FLAP expression 
may be upmodulated after appropriate stimulation of neutrophils. The increase in FLAP expression 
induced by GM-CSF  in inflammatory conditions could confer upon neutrophils a prolonged 
capacity to synthesize leukotrienes. 
T 
he leukotrienes are a family of lipid mediators of inflam- 
mation and allergy that exhibit a diverse range of potent 
biological  effects (1,  2).  Leukotriene (LT)  x B4 is a stereo- 
specific activator of phagocyte function, stimulating chemo- 
taxis, &granulation, adhesion, and aggregation (1, 2), whereas 
the cysteinyl-leukotrienes, LTC4, LTD4, and LTE4 (formerly 
known as the slow-reacting  substance of anaphylaxis), po- 
tently stimulate broncho-constriction and are vasoactive (1, 
2).  Because of the likelihood that  LTB4 is  an  important 
inflammatory mediator,  and that the cysteinyl-leukotrienes 
play a key role in asthma and allergic reactions, considerable 
t Abbreviations used in tkis~per:. AD, actinomycin  D; CX, cycloheximide; 
FLAP, 5-1ipoxygenase-activating  protein; 5-LO, arachidonate 5-1ipoxy- 
genase; LT, leukotriene; rh, recombinant  human; TBS, Tris-buffered  saline. 
effort is still being placed in determining the mechanism by 
which their synthesis is regulated. 
The conversion of free arachidonic acid to leukotrienes in 
phagocytes is controlled by the key enzyme, arachidonate 
5-1ipoxygenase (5-LO) (1-3). Recent studies have revealed  new 
insights into the mechanisms by which the activation of this 
enzyme is regulated in intact cells. In particular,  it was re- 
cently discovered that for leukotriene synthesis to occur, it 
is necessary for the 5-1.O to be translocated from the cytosol 
to membrane structures (4, 5). A second major breakthrough 
occurred with the discovery of a membrane-bound protein, 
termed 5-LO-activating protein (FLAP) (6, 7). Several lines 
of evidence indicate that leukotriene synthesis will not occur 
in intact cells unless FLAP is present (6, 8). Studies involving 
cotransfection of ceUs with FLAP and 5-LO indicate that both 
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8). In addition, the indole derivative, MK 886, which binds 
to FLAP and prevents the translocation of the 5-LO, com- 
pletely inhibits leukotriene synthesis in intact cells (9). The 
results of these studies all suggest that FLAP plays a pivotal 
role in leukotriene synthesis in intact cells. 
FLAP expression in leukotriene-producing cells is thus crit- 
ical for leukotriene synthesis to occur. However, it is not yet 
known whether the level of FLAP protein can be modulated 
in terminally differentiated phagocytes such as neutrophils. 
The 5'-regulatory region of the FLAP gene has recently been 
doned and sequenced (10), and shown to contain several poten- 
tial c/s-regulatory regions characteristic of genes that are regu- 
lated at the transcriptional level. These latter results support 
the contention that the FLAP gene may be modulated in ma- 
ture phagocytes. Since recent studies in our laboratory have 
shown that neutrophils are capable of significant RNA and 
protein synthesis in response to activation by cytokines in- 
cluding GM-CSF and TNF-c~ (11, 12), we have investigated 
the effect of various cytokines on FLAP gene expression in 
human neutrophils. Our data indicated that GM-CSF (and 
to a lesser extent, TNF-a), upregulates FLAP expression in 
a dose- and time-dependent fashion. Incubation of neutro- 
phils with the synthetic glucocorticoid, dexamethasone, also 
led to an increase in FLAP expression. 
Materials  and Methods 
Chemicals.  The 0.84-kb  FLAP cDNA probe cloned into the 
EcoRI site of the Stratagene SK vector (Stratagene, La Jolla, CA) 
and the rabbit polyclonal FLAP antibody were generously supplied 
by Dr. Jillian  Evans and Dr. Philip Vickers of the Merck-Frosst 
Center for Therapeutic Research (Pointe-Claire, Qu6bec, Canada). 
3sS-labeled methionine and cysteine, horseradish peroxidase-linked 
donkey anti-rabbit antibody, and the enhanced chemoluminescence 
(ECL) detection kit were purchased from Amersham Canada (Oak- 
ville, Ontario,  Canada).  Immobilon-P and Hybond-N blotting 
membranes  were  from Millipore  Corp.  (Mississauga,  Ontario, 
Canada). Protein-G Sepharose 4FF was purchased from Pharmacia 
LKB (Montr6al,  Qu6bec, Canada).  RPMI 1640 culture medium 
and FCS were purchased from GIBCO BRL (Burlington, Ontario, 
Canada).  Recombinant human (rh) GM-CSF expressed in Esche. 
richia coli, rhIL-3 and rhlb6 were generous gifts from the Genetics 
Institute (Cambridge, MA). TNF-c~ was a generous gift from Knoll 
Pharmaceuticals (Whippany, NJ). Interferon-3~ was obtained from 
Genentech  Inc. (South San Francisco, CA). Cytokines were kept 
at -20~  as stock solutions in PBS containing 0.01% BSA. Tests 
on these solutions using the Limulus amoebocyte assay for lipopoly- 
saccharide were negative. Hepes, Pipes, EGTA, EDTA, ATE NP- 
40,  Tween-20,  dexamethasone,  cycloheximide  (CX),  and  ac- 
tinomycin D (AD) were purchased from the Sigma Chemical Co., 
(St. Louis, MO). CX was dissolved in DMSO at a concentration 
of 10 rag/m1 and stored at 4~  AD was dissolved in distilled eth- 
anol and kept at 4~  The concentration of the stock solution was 
measured by spectrophotometry. 
Cell Purification.  Peripheral blood was obtained from healthy 
donors using either EDTA or heparin as an anticoagulant, and neu- 
trophils were isolated essentially as described (11-13). The final cell 
suspensions contained <1% monocytes as determined by esterase 
staining,  and the viability was >99%, as determined by Trypan 
Blue exclusion. 
Northern Blot.  Total KNA was purified as previously described 
(12). Briefly, RNA was isolated using a solution of guanidium 
isothiocyanate and centrifugation through a cesium chloride gra- 
dient. The RNA (15 #g/weU) was then run on a 1% agarose gel 
containing formaldehyde, and transferred to Hybond-N membranes 
using a VacuGene  apparatus (Pharmacia LKB). Integrity of the RNA 
and equal  loading were verified by ethidium bromide staining 
and hybridization with glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) or 28S ribosomal  RNA probes. The membranes were 
then hybridized with a FLAP cDNA probe, labeled with [3~]CTP 
using a random primer kit (Amersham Canada). 
Metabolic Labeling and FLAP Imraunoprecipitation.  Neutrophils 
were  suspended  at a cell density of 10S/ml in methionine- and 
cysteine-free RPMI 1640 supplemented  with 0.1% FCS and con- 
taining 200  #Ci/ml  of both  [3SS]methionine and  [3SS]cysteine. 
500-#1 aliquots  were  dispensed  in  1.88-cm  2 culture  wells  and 
treated either with GM-CSF or dexamethasone as indicated in the 
relevant figure legends. Cells were harvested and pelleted and FLAP 
protein was detected by immunoprecipitation essentially as previ- 
ously described (6). 
TCA Precipitation of Proteins.  All steps were performed on ice. 
A small aliquot of each sample from metabolic labeling studies (2-5 
#g of proteins) was pipetted into 1.5-ml (Eppendorf Inc., Fremont, 
CA), along with 100 #1 H20, 100 #1 of BSA as a carrier protein, 
and incorporation of 3ss into total neutrophil proteins was deter- 
mined as previously described (14). 
Two-dimensional  Gel  Electrophoresis and  Western Blot  Proce- 
dures.  The ceils were treated with rhGM-CSF as indicated,  and 
processed for two-dimensional gel dectrophoresis according to the 
method of O'Farrell (15). Equal amounts of total protein, as deter- 
mined using a protein assay (Bin-Red Laboratories, Richmond, CA) 
were loaded onto each gel. The first dimension was run under non- 
equilibrium conditions using 2% ampholite (1:1 [vol/vol] isoelec- 
tric ranges 4-8, and 8-10.5). The samples were migrated for 4,000 
V-h. The second dimension was run on 15% gels, according  to 
the method of Thomas and Kornberg (16). The proteins were trans- 
ferred overnight at a 300 mA current setting onto an Immobilon-P 
(Millipore Corp.) blotting membrane.  The transfer efficiency was 
visualized by Poncean Red staining. The membranes were soaked 
for 1 h at 37~  in tris buffered saline (TBS) (25 mM Tris-HC1, 
pH 7.6, 0.2 M NaC1, 0.15%  Tween 20) containing 2% gelatin 
(wt/vol) as a nonspecific site-blocking agent, and subsequently ex- 
posed to a 1:5,000 dilution of anti-FLAP polyclonal antibody for 
1 h at 37~  The membranes  were then washed twice with 150 
ml of TBS for 15 rain at 25~  and treated with a horseradish per- 
oxidase-linked  donkey anti-rabbit antibody (dilution of 1:7,500) 
in TBS containing 2%  gelatin for 45 min, at 37~  After two 
washes, the signal was revealed using the ECL kit, according to 
the manufacturer's instructions. 
IsolationofNeutroFhilNudei.  Preparations of neutrophil nuclei 
were  obtained as described  by Woods et  al.  (17), with minor 
modifications. Briefly, neutrophil suspensions were centrifuged at 
12,000 g for 5 s, supernatants  were removed and cell pellets (10 
x  10  # cells) were vortexed (5 s), before the progressive addition 
of 300/~1 of NP-lysis buffer (0.1% NP-40,  10 mM Tris-HC1, pH 
7.4,  10 mM NaC1, 3 mM MgCI~, 1 mM EDTA), supplemented 
with the following antiprotease  cocktaih leupeptin (10 #g/m1); 
aprotinin (10 #g/ml); and phenylmethanesulphonyl fluoride (1 mM). 
The samples were kept 5 min on ice, then centrifuged at 500 g 
for 10 min, at 25~  The supernatants (nonnuclear fraction),  and 
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for one-dimension SDS-PAGE (18) and Western blot, as described 
above. Each well was loaded with material corresponding to 5  x 
l0  s cells. 
Results 
Effect of Various Cytokines on the Steady-State Level of  FLAP 
mRNA.  Different cytokines known to activate myeloid cells 
were assessed for their ability to induce an increase in the 
steady-state level of FLAP mKNA. Neutrophfls were treated 
for a  period of 3  h  at  37~  with  each of the following 
cytokines: IL-3; IL-6; IFN-3'; TNF-c~; or GM-CSF (Fig.  1). 
This time point was chosen from the results of previous ki- 
netic studies performed using lipopolysaccharide or GM-CSF 
as an activator (data not shown). Total KNA was then purified 
and the level of FLAP mKNA was determined by Northern 
blotting,  using a 0.84-kb FLAP cDNA probe.  Of all  the 
cytokines tested, only GM-CSF, and to a lesser extent TNF-ot, 
consistently induced  a  significant  accumulation  of FLAP 
mKNA.  We therefore designed additional experiments in 
order to further characterize this effect of GM-CSF. 
Neutrophils were treated for the indicated periods of time 
with 3 nM GM-CSF or its diluent (0.01% BSA) at 37~ 
This concentration of the cytokine was chosen from the results 
of previous experiments on neutrophils performed in this lab- 
oratory using GM-CSF (11, 12). In these experiments, GM- 
CSF induced an increase in the steady-state level of FLAP 
mKNA in a time-dependent manner (Fig. 2). Over six inde- 
Figure 2.  Effect  of time of incubation with GM-CSF on the steady- 
state level  of  FLAP  mKNA. Nentrophils  were  incubated  for the indicated 
periods of time in the presence of 3 nM GM-CSF or its diluent, total 
KNA was isolated, and Northern  blots performed  to detect  FLAP  mRNA, 
as described  in the legend  to Fig. 1. These  results are from one representa- 
tive experiment of four separate experiments. 
pendent experiments, a significant increase in FLAP mRNA 
was detectable between 30 min and 1 h  of GM-CSF treat- 
ment. This stimulatory effect was observed for up to 4  h. 
After 16 h, the levels of  FLAP mKNA were significantly lower. 
The stimulatory effect of GM-CSF was also dose dependent, 
with  a maximal effect being observed using 3  nM  of the 
cytokine (data not shown). Neutrophils were also preincubated 
with 20/~g/ml of the protein synthesis inhibitor, CX before 
being exposed to GM-CSE CX failed to prevent the increased 
accumulation of FLAP mRNA induced by GM-CSF (Fig. 
3). In fact, prior treatment of the cells with CX increased 
the accumulation of FLAP mRNA induced by GM-CSF in 
an additive manner. By itsdf, CX slightly increased the level 
of FLAP mRNA.  Incubation of calls with 5 t~g/ml of the 
transcription inhibitor, AD completely inhibited the accumu- 
lation of FLAP mtLNA induced by GM-CSF. 
Effect of GM-CSF on the Accumulation of  Newly Synthesized 
FLAP.  Neutrophils were treated with 3 nM GM-CSF for 
Figure 1.  Effect  of  different  cytokines  on the steady-state  level  of  FLAP 
mRNA. Nentrophils  were  incubated  with the indicated  cytokines  for 3 h 
and total RNA was isolated. FLAP mR.NA was detected  by Northern 
blot. Integrity of the RNA and equal loading were verified  by ethidium 
bromide  staining,  and hybridization  with 28S ribosomal  RNA probe,  respec- 
tivdy. The cells  were incubated with the following  cytokines: GM-CSF 
(3 riM); TNF-~ (100 ng/ml); IFN-3, (100 ng/ml); Ib3 (200 U/ml); or 
IL-6 (15 ng/ml). These  data are from  one representative  experiment  of  four 
separate experiments. 
Figure 3.  Effect of CX and AD on the steady-state  level of FLAP 
mRNA. Nentrophils  were incubated  for 4 h with 3 nM GM-CSF in the 
presence or absence  of either 20/~g/mi CX or 5/~g/ml AD. Total  KNA 
was isolated, and Northern blots performed  to detect FLAP mRNA, as 
described  in the legend  to Fig. 1. These  results  are from one representative 
experiment of seven separate experiments. 
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of GM-CSF on the de novo syn- 
thesis of FLAP. Nentrophil sus- 
pensions  in  RPMI  1640 sup- 
plemented  with 0.1%  FCS and 
3sS-labeled  amino  acids  were 
treated with 3 nM GM-CSF (or 
its diluent) for various periods of 
time.  Cells were then harvested 
and 3sS-labeled  FLAP was immu- 
noprecipitated, processed for SDS- 
PAGE, and analyzed by autoradi- 
ography as described in Materials 
and Methods. (A) Immunoprecip- 
itation showing the de novo syn- 
thesis of FLAP by nentrophils in 
response to stimulation by GM- 
CSF for 6 h.  (B) Densitometric 
analysis  showing the effect of  time 
of incubation with GM-CSF on 
the de novo synthesis of FLAP. 
These results are from one experi- 
ment, representative  of  five  experi- 
ments.  IOD,  integrated  optical 
density. 
up to 6 h at 37~  in the presence of [3SS]methionine and 
[3SS]cysteine, and  FLAP  immunoprecipitations  were  per- 
formed. GM-CSF enhanced the accumulation of newly syn- 
thesized FLAP (Fig. 4 A). An increased incorporation of 3sS 
amino acids into FLAP was consistently  observed after 2 h 
of GM-CSF treatment, and continued  to increase for up to 
6 h in the presence of the cytokine (Fig. 4 B). GM-CSF con- 
sistently failed to induce a detectable accumulation of newly 
synthesized FLAP at time points shorter than 2 h (data not 
shown). Incubation of the cells with either AD or CX be- 
fore treatment with GM-CSF completely blocked the increase 
in newly synthesized  FLAP (data not shown). 
Dose-response experiments were conducted in which cells 
were treated for 6 h in the presence of various concentrations 
of GM-CSF. The results of these experiments showed that 
the increased de novo synthesis of FLAP was dependent upon 
the concentration of GM-CSF. In three independent experi- 
ments,  the minimum  concentration required to induce the 
de novo  synthesis of FLAP was 30 pM,  and de novo  syn- 
thesis was nearly maximal at 300 pM GM-CSF  (Fig. 5, A 
and B). 
To verify that the effect of GM-CSF on the de novo syn- 
thesis of FLAP was specific, total cell protein was obtained 
by TCA precipitation in each experiment,  and the incorpo- 
ration of [3SS]methionine and cysteine was determined. Over 
a total of 11 separate experiments in which neutrophils were 
exposed to GM-CSF for up to 6 h,  no significant enhance- 
ment of the incorporation  of [3SS]methionine and [3SS]cys- 
teine into total neutrophil protein was observed. The value 
for GM-CSF-treated neutrophils was 104  _+  10% (mean + 
SEM) of the control  value. 
Effect of  GM-CSF on the Total  FLAP Protein Content of  Neu- 
trophils.  The effect of GM-CSF  on the total cellular level 
of FLAP in neutrophils was investigated in control and GM- 
CSF-treated neutrophils by Western blot in order to verify 
Figure 5.  Effect  of concentration  of GM-CSF on the de novo synthesis 
of FLAP. Nentrophils were treated for 6 h in the presence of various con- 
centrations of GM-CSF (or its diluent), and 3sS-labeled FLAP was im- 
munoprecipitated as described in the legend to Fig. 4. (A) Immunopreci- 
pition showing the de novo synthesis of FLAP by nentrophfls in response 
to stimulation with increasing concentrations of GM-CSF. (B) Densito- 
metric analysis of the autoradiograms shown in A. These results are from 
one experiment,  representative of five separate experiments. 
Figure 6.  Effect  of GM-CSF on the total cellular FLAP levels  in whole 
neutrophils  and nentrophil nuclei. (A) Nentrophils were incubated for 
6 h in the absence  (/eft), or presence  of 3 nM GM-CSF (right). Equal amounts 
of total cellular proteins were then separated by two-dimensional gel elec- 
trophoresis and FLAP was detected by Western blot. This experiment is 
representative of five separate  experiments. (B) Neutrophils were incubated 
with GM-CSF for indicated times, and nuclei were prepared and processed 
for SDS-PAGE  as described  in Materials  and Methods. N, nuclear-containing 
fraction; NN, nonnuclear fraction.  This experiment is representative of 
four separate experiments. 
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with (and  without) 20/~g/ml  CX for up to 20 h. Nuclei were then pre- 
pared and processed  for SDS-PAGE  as described  in Materials  and Methods. 
These results are from  one representative  experiment of four separate ex- 
periments. 
whether the increased FLAP expression induced by GM-CSF 
was of sufficient magnitude to influence the total cellular pool 
of FLAP. Cells were therefore incubated for 6 h in the pres- 
ence of GM-CSF or its diluent, and two-dimensional SDS- 
PAGE were performed. Equal amounts of total cellular pro- 
teins were loaded on each gel, as measured by a protein assay. 
Under these conditions, a single spot with a molecular mass 
of ~18 kD and an isoelectric  point in the 7-9 range, corre- 
sponding to the migration point of FLAP, was detected (Fig. 
6 A). Incubation with GM-CSF significantly increased  the 
overall quantity of FLAP present in intact neutrophils (Fig. 
6 A, right), relative  to control cells. Densitometric analysis 
for FLAP revealed  a 5.8-fold  +  2.5  (mean  +_  SEM,  n  = 
5) increase in GM-CSF-treated neutrophils, as compared with 
the control. 
In recent electron microscopy studies, FLAP was found 
to be localized in the nuclear envelope of neutrophils (17). 
We therefore performed additional experiments to assess that 
the increased  expression  of FLAP could be specifically ob- 
served in a neutrophil subcellular fraction containing intact 
nuclei. Neutrophils were treated with GM-CSF (or diluent), 
fractions containing nuclei as well as the corresponding non- 
nuclear fractions were obtained and processed  for Western 
blot. In n =  4 experiments, FLAP expression was significantly 
increased in the nuclei of neutrophils treated with GM-CSF 
for 6 h, as compared with control neutrophils (Fig.  6 B). 
At no time was FLAP observed in the nonnudear fraction. 
Assessment of FLAP Stability in Neutrophils.  Neutrophils 
were incubated in the presence (or absence) of 20 #g/ml CX 
for increasing periods of time (up to 20 h), and nudear prepa- 
rations were processed  for Western blot.  In four indepen- 
dent experiments,  no significant decrease of FLAP levels could 
be observed, either in control or CX-treated cells (Fig. 7). 
This demonstrated that FLAP is a relatively stable protein 
in human neutrophils. It was concluded that the effect of 
GM-CSF on FLAP levels observed  in short term exposure 
(6 h) of neutrophils to the cytokine were the consequence 
of enhanced de novo synthesis of the protein rather than pro- 
tein stabilization. 
Regulation of FLAP Expression by Dexamethasone.  It has 
recently been shown that the FLAP gene contains a putative 
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Figure  8.  Effects  ofdexamethasone  on FLAP  expression.  (A) Effect  of 
dexamethasone on FLAP mRNA steady-state  levels. Neutrophils were 
treated with 100 nM dexamethasone  and/or 3 nM GM-CSF, for 4 h. 
Northern blots were then performed to determine the levels of FLAP 
mkNA. This  result  is from  one experiment,  representative  of  five  separate 
experiments. (/3) Effect  of  degamethasone  on the de novo  synthesis  of  FLAP. 
Neutrophils were  treated  with 100 nM dexamethasone  and/or  3 nM GM- 
CSF in the presence of [3SSlmethionine  and [3sS]cysteine,  and FLAP  was 
immunoprecipitated  and analyzed  as described in the legend to Fig. 4. 
Alternatively,  neutrophils  were  pretreated  with CX (20/~g/ml)  before  in- 
cubation  with dexamethasone.  These  results  are from  one experiment,  rep- 
resentative of four separate experiments.  (C) Effect  of dexamethasone  on 
FLAP  expression  in neutrophil  nuclei.  Neutrophils  were  treated  with GM- 
CSF and/or  dexamethasone  for 6 h and nucld  were  prepared  and processed 
as described  in Materials  and Methods.  These  results are from  one experi- 
ment, representative  of four separate experiments. 
glucocorticoid-responsive  element (GRE) in its 5'-regulatory 
region (10). In view of the fact that glucocorticoids are po- 
tent antiinflammatory  agents and leukotrienes are considered 
proinflammatory, we investigated whether the synthetic glu- 
cocorticoid, dexamethasone, could downmodulate the expres- 
sion of FLAP. Cells were therefore treated with 100 nM dexa- 
methasone, in the presence  or absence  of 3 nM GM-CSF, 
for 4 h at 37~  Under these conditions, dexamethasone by 
itself increased FLAP mRNA steady-state levels when com- 
pared with control samples, as determined by Northern blot 
(Fig.  8 A).  Coincubation of GM-CSF and dexamethasone 
caused an additive increase in the level of the FLAP mRNA, 
when compared with the effect of either agent alone. Prein- 
cubation of the cells with the protein synthesis inhibitor, CX, 
did not block the effect of dexamethasone on the level of  FLAP 
mRNA. In contrast, AD (5/zg/ml) completely blocked the stimulator), effect of dexamethasone on the accumulation of 
FLAP mRNA (data not shown). 
In protein-labeling experiments, in which both control- 
and GM-CSF-treated neutrophils were incubated for 4 h in 
the presence of dexamethasone, an increase in the de novo 
synthesis of FLAP was observed in dexamethasone-treated 
cells (Fig. 8 B). In these experiments, preincubation of the 
neutrophils with CX (20 #g/ml) completely abolished the 
de novo synthesis of FLAP. In addition, nuclear preparations 
from neutrophils incubated with 100 nM dexamethasone for 
6 h showed a significant increase of FLAP level (Fig. 8 C), 
as compared with diluent-treated neutrophils. 
Discussion 
The leukotrienes are a family of lipid mediators involved 
in inflammation, allergy and asthma (1, 2).  The synthesis 
of these compounds is critically dependent upon the activa- 
tion of the arachidonate 5-LO. A growing body of evidence 
suggests  that  the  participation  of a  recently  discovered 
membrane-bound  protein, termed FLAP, is required for leu- 
kotriene synthesis to occur in intact cells (6-9).  Although 
the precise role of FLAP has not yet been defined, the latest 
evidence indicates that it may facilitate substrate presentation 
to the 5-LO (19). To date, most studies on FLAP have fo- 
cused on the functional aspects of this molecule. Since little 
is currently known concerning the regulation of FLAP in 
terminal/y differentiated phagocytes, we have conducted studies 
to determine whether FLAP expression could be physiologi- 
cally modulated in peripheral blood neutrophils, a cell type 
that is one of the major producers of LTB4 in the immune 
system (2, 3). 
In previous studies, we have shown that amidst a wide 
array of neutrophil agonists, GM-CSF was one of only three 
that were capable of stimulating a significant RNA synthesis 
in these ceils, the other two being the formylated oligopep- 
tide fMet-Leu-Phe, and the multifunctional cytokine TNF-ol 
(11). However, we observed that GM-CSF was by far the most 
potent on the de novo synthesis of a sdect number of pro- 
teins (12). We and others subsequently identified several of 
these proteins as the IL-1 receptor antagonist (12), cationic 
antimicrobial protein (20), actin (21), and MHC class II (22). 
In the present report, we have determined that FLAP expres- 
sion in neutrophils is also selectively upregulated by GM- 
CSF. Several  other cytokines, including IFN~, II,-3, and IL-6, 
consistently failed to stimulate the accumulation of FLAP 
mRNA. This selective upregnlation by GM-CSF of protein 
synthesis in neutrophils was further assessed in the present 
study  when  we  examined  the  overall  incorporation  of 
[3SS]methionine and [3SS]cysteine  into total cellular proteins. 
The amount of [3sS]amino adds incorporated into the TCA- 
precipitable fraction in GM-CSF-treated neutrophils was not 
significantly different from that in diluent-treated calls, yet 
in the same experiments, a significant  de novo synthesis of 
FLAP was observed in GM-CSF-treated cells. This latter re- 
sult is important in that it confirms that the effect of GM- 
CSF on protein expression in neutrophils is relatively specific 
and restricted to a limited number of target proteins (21, 23). 
Whereas the mechanism by which GM-CSF increases the 
steady-state level of FLAP mRNA has not been conclusively 
established, pretreatment of human neutropkils with CX failed 
to prevent the upregulation of FLAP mRNA by GM-CSF, 
suggesting that the effect of GM-CSF on FLAP mRNA is 
not dependent on the synthesis of other proteins. Moreover, 
the increased expression  of FLAP mRNA was completely 
inhibited by the transcription inhibitor AD, suggesting in- 
creased FLAP mRNA synthesis. Further studies are required 
to define the exact mechanism by which GM-CSF enhances 
FLAP expression in neutrophils. 
In view of the fact that FLAP is crucial for leukotriene 
synthesis to occur in intact neutrophils, the question of the 
potential physiological relevance of an increased de novo syn- 
thesis of FLAP in neutrophils in response to GM-CSF arises. 
Over the last few years, several reports have documented that 
pretreating human neutrophils with GM-CSF strongly en- 
hances leukotriene synthesis in response to second agonists. 
In these studies, a maximal priming for leukotriene synthesis 
was observed when neutrophils were pretreated with GM- 
CSF for between 30 min and 1 h (depending on the condi- 
tions of incubation), after which the priming effect rapidly 
decreased (24-26).  In the present study, an increase in the 
de novo synthesis of FLAP was not observed until after 2 h 
of incubation with GM-CSF.  Moreover,  the level of FLAP 
protein continued to increase for the total length of the ex- 
periment (6 h) after exposure to GM-CSF.  The difference 
between the time course reported for the priming by GM- 
CSF for increased leukotriene synthesis, and that for the de 
novo synthesis of FLAP, indicates that the effect of GM-CSF 
on FLAP expression is unlikely to be involved in the priming 
for increased leukotriene synthesis observed in short-term in- 
cubations in vitro. However, it must be stressed that little 
is known concerning the turnover and fate of proteins of the 
5-1s  pathway, including FLAP, over prolonged periods of 
time in neutrophils, nor are the long-term effects of GM- 
CSF on leukotriene synthesis by neutrophils in vivo known. 
Since leukotriene synthesis requires the participation of FLAP, 
our data raise the possibility that the increase in FLAP ex- 
pression in response to GM-CSF could play a significant long- 
term role in enhancing or maintaining leukotriene synthesis 
by neutrophils, in response to subsequent stimulation. The 
ability of GM-CSF to increase neutrophil survival in vitro 
(27), possibly via inhibition of apoptosis (28), further sup- 
ports the contention that prolonged synthesis of FLAP may 
occur in vivo. Such a scenario may be particularly relevant 
at sites of acute and chronic inflammation, where neutro- 
phils may be subject to long-term exposure to relatively high 
levels of GM-CSF (29). 
Glucocorticoids are a class of widely used antiinflamma- 
tory drugs that profoundly affect the inflammatory response 
by exerting both inhibitory and stimulatory effect on the ex- 
pression of certain genes (30). Kennedy et al. (10), have re- 
cently cloned, sequenced, and begun to functionally charac- 
terize  the 5'-regulatory region of the FLAP gene. Several 
potential c/s-regulatory  regions were identified, including 
potential binding sites for the nuclear transcription factor AP-2 
at positions  -482 to  -475 bp, and for the glucocorticoid 
1230  GM-CSF  Increases 5-Lipoxygenase-activating  Protein Expression receptor complex at positions  -563 to  -556 bp (10). The 
presence of this latter c/s-regulatory element prompted us to 
examine the effect of the synthetic glucocorticoid dexameth- 
asone on FLAP expression in neutrophils. In these studies, 
we sought to determine whether dexamethasone would in- 
hibit FLAP expression induced by GM-CSF, an effect which 
would have been in keeping with an antiinflammatory ac- 
tion of dexamethasone. However, we observed  that incuba- 
tion of neutrophils with dexamethasone resulted in a direct 
increase in the FLAP mRNA level and in the expression  of 
FLAP. Moreover, the combined effect of dexamethasone and 
GM-CSF was to additively enhance FLAP expression. The 
results of these experiments reemphasize the complexity of 
the action of glucocorticoids by demonstrating that not all 
of the effects of these compounds are necessarily antiinflamma- 
tory in nature. 
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